Agenda
*All times are in PDT
Aug
Fri 25
Welcome reception
Aug
Sat 26
Meeting objectives & introduction
Naval Daver & Andrew Wei
Session 1: New research perspectives in AML
Chairs: Ravi Majeti & Iannis Aifantis
- Clonal Evolution in AML: Ravi Majeti
- Predictors of transformation in CHIP and CCUS and ways to optimize prediction: Koichi Takahashi
- Potential for early intervention in CHIP and CCUS: Uma Borate
Panel discussion
- Familial leukemia predispositions: understanding, identifying, and monitoring: Courtney DiNardo
- Harnessing epigenetic information in AML to identify novel potential therapeutic approaches: Maria “Ken” Figueroa
- Deconvoluting clonal and cellular architecture in IDH-mutant AML: Iannis Aifantis
- Ancestry-inclusive consideration of AML genomics: Ann-Kathrin Eisfeld
Panel discussion
Break
Session 2: Controversies in AML
Chairs: Gail Roboz & Naval Daver
- Improving intensive chemotherapy approaches in frontline AML: Tapan Kadia
- Which patients should have allogeneic transplants in 2023?: Charles Craddock
- Intensive chemo or HMA + VEN intermediate for younger AML patients?: Eunice Wang
- Keeping AML patients in remission – maintenance vs transplant: Gail Roboz
Panel discussion
- Optimizing therapy in secondary AML and optimal use of CPX-351: Tara Lin
- Clinical approaches for IDH-mutated AML: Eytan Stein
- Frontline approaches for FLT3-mutant AML: Harry Erba
- Current approaches for relapsed FLT3-mutant AML: Jessica Altman
Panel discussion
Session 3: New frontiers in MRD for AML clinical practice
Chairs: Richard Stone & Marina Konopleva
- Single-cell sequencing and clinical applicability in detection and therapy of AML: Catherine Smith
- Value of MRD assessment in non-intensive regimens in AML: Farhad Ravandi-Kashani
- Value of MRD assessment in intensive regimens in AML: Maximillian Stahl
- MRD as a clinical endpoint in clinical trials: Roland Walter
- Applying MRD techniques in FLT3 mutated AML – are we able to use MRD as an endpoint in FLT3 AML?: Alexander Perl
- MRD-directed interventions: Andrew Wei
Panel discussion
Lunch
Session 4: BPDCN & MDS/MPN + CMML
Chairs: Naveen Pemmaraju & Mrinal Patnaik
- Updates in diagnosis, pathogenesis and future directions in BPDCN: Naveen Pemmaraju
- Current and new directions for accelerated/BP/transformed MPN: Anand Patel
- VEXAS: a new entity: Emma Groarke
- Future targets and drug development in CMML: Mrinal Patnaik
- Bench to bedside in MPNs: CALR and targeting CALR: Naveen Pemmaraju
- Novel targeted Agents in MPNs: Raajit Rampal
Panel discussion
Break
Session 5: Novel targets, combinations and treatments in AML
Part 1 – new AML therapies and limitations
Chairs: Andrew Wei and Eunice Wang
Keynote talk
History of development and future directions for FLT3 inhibitors in AML: Mark Levis
New AML therapies and limitations
- Optimizing doublet and triplet combinations in AML – improving efficacy while maintaining safety: Naval Daver
- Uproleselan in frontline and R/R AML: Geoffrey Uy
- TP53 treatment strategies in AML: Thomas Cluzeau
Panel discussion
- Menin inhibitors in AML: Ghayas Issa
- Mechanisms of resistance and combination approaches with menin inhibitors in AML: Eytan Stein
- Targeting resistance to venetoclax-based therapies: Marina Konopleva
- Resistance to FLT3 inhibitors: Catherine Smith
Panel discussion
Day 1 ends
Aug
Sun 27
Introduction to Day 2
Naval Daver & Andrew Wei
Session 6: Special session on regulatory endpoints in AML
Chairs: Courtney DiNardo & Mark Levis
- The FDA’s perspective on regulatory endpoints in AML: Joseph Wynne
- A clinical investigator’s perspective on endpoints and drug development in AML: Naval Daver
Panel discussion including Kelly Norsworthy
Session 7: Novel targets, combinations, and treatments in AML
Part 2 – what do we know about drug resistance?
Chairs: Charles Craddock & Courtney DiNardo
- Genomic landscape and prognostic implications of TP53 mutations in AML: Sanam Loghavi
- p53 reactivators and magrolimab in TP53-mutant MDS/AML: David Sallman
- Novel pro-survival combinations: Andrew Wei
Break
Session 8: Transplant and immunotherapies in AML
Chairs: Charles Craddock & David Sallman
- Vedolizumab for prophylaxis and treatment of acute GvHD post-alloSCT: Yngvar Fløisand
- Updates in the use of post-transplant cyclophosphamide: Nelli Bejanyan
- Which patients with AML in MRD+ CRi should be transplanted?:Roland Walter
- Lessons from the MORPHO trial: Mark Levis
- Novel T-cell approaches for R/R AML (excluding CAR-T): Nelli Bejanyan
- Early phase CAR-T and NK cell trials for R/R AML and MDS: David Sallman
Panel discussion
Meeting conclusions & final remarks